Pfizer’s complaint about Alnylam’s activities at a cardiology congress has led the PMCPA to chastise the | Pfizer’s complaint about Alnylam’s activities at a cardiology congress has led the PMCPA to chastise the biotech, although the U.K. marketing watchdog overturned its severest criticism on appeal.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
The U.K. | The U.K. pharma marketing watchdog has slammed AGB Pharma for misleadingly implying a lack of fertility considerations…
Following an inspection earlier this year that yielded a Form 483, Indian generics juggernaut Alembic Pharmaceuticals has…
Alnylam Pharmaceuticals’ stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a lowered…
As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed…
On the heels of a European Commission probe into whether Sanofi “disparaged” one of its flu vaccine rivals in the marketing of…
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has…
